Increased serum BDNF and ProBDNF levels in children with irritable bowel syndrome

Basit Öğe Kaydı
dc.authorscopusid55175886400
dc.authorscopusid55315126400
dc.authorscopusid8240771400
dc.authorscopusid36523620300
dc.authorscopusid27967486000
dc.authorscopusid29067508300
dc.contributor.authorŞenkal, Evrim
dc.contributor.authorDurankuş, Ferit
dc.contributor.authorÇam, Sebahat
dc.contributor.authorPotas, Nihan
dc.contributor.authorBeyazyüz, Murat
dc.contributor.authorAlbayrak, Yakup
dc.date.accessioned2022-05-11T14:05:08Z
dc.date.available2022-05-11T14:05:08Z
dc.date.issued2020
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders among the pediatric population. Recently, neurotrophins have been suggested to be etiological factors or causes of symptoms of IBS. In the present study, the aim was to research the serum brain-derived neurotrophic factor (BDNF) and proBDNF levels in children with IBS. Methods: The study group was selected from pediatric gastroenterology outpatient clinic and control group was recruited from healthy children outpatient clinic. Based on the inclusion and exclusion criteria, 29 children with IBS and 55 healthy children were included in the study. The data were obtained from all participants, and if needed, from their parents. All participants were assessed in terms of anthropometric measurements. The serum (BDNF) and proBDNF levels were compared between the groups. Results: The proBDNF levels in IBS patients were higher compared with the control group in covariance analysis (IBS patients group mean 492.4, SD 534.1; control group mean 332.8, SD 406.7) (p = 0.02; Cohen's d = 0.45). The serum BDNF levels of IBS patients were also higher compared with the control group (IBS patients group mean 3.1, SD 4.3; control group mean 1.7, SD 2.7) (p = 0.02; Cohen's d = 0.51). Conclusions: The present study is the first to demonstrate that there is a higher level of serum BDNF in children with IBS. Moreover, it is the first to demonstrate an increased level of proBDNF in IBS. Additional research is needed to confirm the preliminary results. © 2020 Elsevier Inc.
dc.identifier.doi10.1016/j.jpsychores.2020.110216
dc.identifier.issn0022-3999
dc.identifier.pmid32829103
dc.identifier.scopus2-s2.0-85089534326
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.jpsychores.2020.110216
dc.identifier.urihttps://hdl.handle.net/20.500.11776/4903
dc.identifier.volume137
dc.identifier.wosWOS:000570288000010
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorBeyazyüz, Murat
dc.institutionauthorAlbayrak, Yakup
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofJournal of Psychosomatic Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBDNF
dc.subjectBiomarker
dc.subjectChildren
dc.subjectIrritable bowel
dc.subjectbrain derived neurotrophic factor
dc.subjectpro brain derived neurotrophic factor
dc.subjectunclassified drug
dc.subjectArticle
dc.subjectchild
dc.subjectchildhood disease
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectfemale
dc.subjecthuman
dc.subjectirritable colon
dc.subjectmale
dc.subjectoutpatient department
dc.titleIncreased serum BDNF and ProBDNF levels in children with irritable bowel syndrome
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4903.pdf
Boyut:
867.76 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu